Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression

Science Signaling

Volumn 9, Issue 422, 2016, Pages

  Morales, Cyndi R ^a   Li, Dan L ^a   Pedrozo, Zully ^a,b   May, Herman I ^a   Jiang, Nan ^a   Kyrychenko, Viktoriia ^a   Cho, Geoffrey W ^a   Kim, Soo Young ^a   Wang, Zhao V ^a   Rotter, David ^a   Rothermel, Beverly A ^a,c   Schneider, Jay W ^a   Lavandero, Sergio ^a,b   Gillette, Thomas G ^a   Hill, Joseph A ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHILE   (Chile)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTININ; HISTONE DEACETYLASE 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; TROPONIN I; TUBEROUS SCLEROSIS COMPLEX 2; UNCLASSIFIED DRUG; APICIDIN; CYCLOPEPTIDE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; TARGET OF RAPAMYCIN KINASE; TUBERIN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GENE SILENCING; GENETIC TRANSCRIPTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; THORACIC AORTIC CONSTRICTION; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE CELL; CARDIOMEGALY; CELL CULTURE; CELL LINE; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; NEWBORN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; CARDIOMEGALY; CELL LINE; CELLS, CULTURED; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYOCYTES, CARDIAC; PEPTIDES, CYCLIC; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84963612261     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aad5736     Document Type: Article

References (41)

1. D. Mozaffarian, E. J. Benjamin, A. S. Go, D. K. Arnett, M. J. Blaha, M. Cushman, S. R. Das, S. de Ferranti, J.-P. Després, H. J. Fullerton, V. J. Howard, M. D. Huffman, C. R. Isasi, M. C. Jiménez, S.E. Judd, B. M. Kissela, J.H. Lichtman, L. D. Lisabeth, S. Liu, R. H. Mackey, D. J. Magid, D. K. McGuire, E. R. Mohler III, C.S. Moy, P. Muntner, M. E. Mussolino, K. Nasir, R. W. Neumar, G. Nichol, L. Palaniappan, D. K. Pandey, M. J. Reeves, C. J. Rodriguez, W. Rosamond, P.D. Sorlie, J. Stein, A. Towfighi, T.N. Turan, S. S. Virani, D. Woo, R.W. Yeh, M. B. Turner; American heart Association Statistics Committee and Stroke Statistics Subcommittee, Heart disease and stroke statistics-2016 update: A report from the American Heart Association. Circulation 133, e38-e360 (2016).
2. Y. Kong, P. Tannous, G. Lu, K. Berenji, B. A. Rothermel, E. N. Olson, J. A. Hill, Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 113, 2579-2588 (2006).
3. N. Frey, H. A. Katus, E. N. Olson, J. A. Hill, Hypertrophy of the heart: A new therapeutic target? Circulation 109, 1580-1589 (2004).
4. G. G. Schiattarella, J. A. Hill, Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. Circulation 131, 1435-1447 (2015).
5. C. L. Antos, T. A. McKinsey, M. Dreitz, L. M. Hollingsworth, C.-L. Zhang, K. Schreiber, H. Rindt, R. J. Gorczynski, E. N. Olson, Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J. Biol. Chem. 278, 28930-28937 (2003).
6. D. J. Cao, Z. V. Wang, P. K. Battiprolu, N. Jiang, C. R. Morales, Y. Kong, B. A. Rothermel, T. G. Gillette, J. A. Hill, Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc. Natl. Acad. Sci. U.S.A. 108, 4123-4128 (2011).
7. P. Gallo, M. V. G. Latronico, P. Gallo, S. Grimaldi, F. Borgia, M. Todaro, P. Jones, P. Gallinari, R. De Francesco, G. Ciliberto, C. Steinkühler, G. Esposito, G. Condorelli, Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc. Res. 80, 416-424 (2008).
8. S. Wedel, L. Hudak, J.-M. Seibel, J. Makarević, E. Juengel, I. Tsaur, C. Wiesner, A. Haferkamp, R. A. Blaheta, Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin. Exp. Metastasis 28, 479-491 (2011).
9. T. Shioi, J. R. McMullen, O. Tarnavski, K. Converso, M. C. Sherwood, W. J. Manning, S. Izumo, Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107, 1664-1670 (2003).
10. K. R. Boheler, S. Bhattacharya, E. M. Kropp, S. Chuppa, D. R. Riordon, D. Bausch-Fluck, P. W. Burridge, J. C. Wu, R. P. Wersto, G. C. F. Chan, S. Rao, B. Wollscheid, R. L. Gundry, A human pluripotent stem cell surface N-glycoproteome resource reveals markers, extracellular epitopes, and drug targets. Stem Cell Rep. 3, 185-203 (2014).
11. R. L. Montgomery, C. A. Davis, M. J. Potthoff, M. Haberland, J. Fielitz, X. Qi, J. A. Hill, J. A. Richardson, E. N. Olson, Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 21, 1790-1802 (2007).
12. C. V. Segré, S. Chiocca, Regulating the regulators: The post-translational code of class I HDAC1 and HDAC2. J. Biomed. Biotechnol. 2011, 690848 (2011).
13. T. Watanabe-Asano, A. Kuma, N. Mizushima, Cycloheximide inhibits starvationinduced autophagy through mTORC1 activation. Biochem. Biophys. Res. Commun. 445, 334-339 (2014).
14. D. D. Sarbassov, S. M. Ali, D. M. Sabatini, Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17, 596-603 (2005).
15. D. D. Sarbassov, S. M. Ali, D.-H. Kim, D. A. Guertin, R. R. Latek, H. Erdjument-Bromage, P. Tempst, D. M. Sabatini, Rictor, a novel binding partner of mTOR, defines a rapamycininsensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302 (2004).
16. T. R. Peterson, M. Laplante, C. C. Thoreen, Y. Sancak, S. A. Kang, W. M. Kuehl, N. S. Gray, D. M. Sabatini, DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137, 873-886 (2009).
17. M. Miyazaki, K. A. Esser, REDD2 is enriched in skeletal muscle and inhibits mTOR signaling in response to leucine and stretch. Am. J. Physiol. Cell Physiol. 296, C583-C592 (2009).
18. X. Lian, J. Zhang, S. M. Azarin, K. Zhu, L. B. Hazeltine, X. Bao, C. Hsiao, T. J. Kamp, S. P. Palecek, Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat. Protoc. 8, 162-175 (2013).
19. J. E. Bolden, M. J. Peart, R. W. Johnstone, Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769-784 (2006).
20. P. Quan, F. Moinfar, I. Kufferath, M. Absenger, T. Kueznik, H. Denk, K. Zatloukal, J. Haybaeck, Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K/AKT/mTOR signaling. Anticancer Res 34, 2883-2897 (2014).
21. A. Farria, W. Li, S. Y. R. Dent, KATs in cancer: Functions and therapies. Oncogene 34, 4901-4913 (2015).
22. T. G. Gillette, J. A. Hill, Readers, writers, and erasers: Chromatin as the whiteboard of heart disease. Circ. Res. 116, 1245-1253 (2015).
23. M. Xie, J. A. Hill, HDAC-dependent ventricular remodeling. Trends Cardiovasc. Med. 23, 229-235 (2013).
24. C. Colussi, B. Illi, J. Rosati, F. Spallotta, A. Farsetti, A. Grasselli, A. Mai, M. C. Capogrossi, C. Gaetano, Histone deacetylase inhibitors: Keeping momentum for neuromuscular and cardiovascular diseases treatment. Pharmacol. Res. 62, 3-10 (2010).
25. T. A. McKinsey, Therapeutic potential for HDAC inhibitors in the heart. Annu. Rev. Pharmacol. Toxicol. 52, 303-319 (2012).
26. D. Siegel, M. Hussein, C. Belani, F. Robert, E. Galanis, V. M. Richon, J. Garcia-Vargas, C. Sanz-Rodriguez, S. Rizvi, Vorinostat in solid and hematologic malignancies. J. Hematol. Oncol. 2, 31 (2009).
27. M. Xie, Y. Kong, W. Tan, H. May, P. K. Battiprolu, Z. Pedrozo, Z. V. Wang, C. Morales, X. Luo, G. Cho, N. Jiang, M. E. Jessen, J. J. Warner, S. Lavandero, T. G. Gillette, A. T. Turer, J. A. Hill, Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. Circulation 129, 1139-1151 (2014).
28. C. M. Trivedi, Y. Luo, Z. Yin, M. Zhang, W. Zhu, T. Wang, T. Floss, M. Goettlicher, P. R. Noppinger, W. Wurst, V. A. Ferrari, C. S. Abrams, P. J. Gruber, J. A. Epstein, Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3b activity. Nat. Med. 13, 324-331 (2007).
29. J. R. McMullen, M. C. Sherwood, O. Tarnavski, L. Zhang, A. L. Dorfman, T. Shioi, S. Izumo, Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109, 3050-3055 (2004).
30. D. Zhang, R. Contu, M. V. G. Latronico, J. Zhang, R. Rizzi, D. Catalucci, S. Miyamoto, K. Huang, M. Ceci, Y. Gu, N. D. Dalton, K. L. Peterson, K.-L. Guan, J. H. Brown, J. Chen, N. Sonenberg, G. Condorelli, MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J. Clin. Invest. 120, 2805-2816 (2010).
31. A. Das, F. N. Salloum, S. M. Filippone, D. E. Durrant, G. Rokosh, R. Bolli, R. C. Kukreja, Inhibition of mammalian target of rapamycin protects against reperfusion injury in diabetic heart through STAT3 signaling. Basic Res. Cardiol. 110, 31 (2015).
32. Z. Yang, D. J. Klionsky, Mammalian autophagy: Core molecular machinery and signaling regulation. Curr. Opin. Cell Biol. 22, 124-131 (2010).
33. K. Inoki, Y. Li, T. Xu, K.-L. Guan, Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17, 1829-1834 (2003).
34. A. J. Malhowski, H. Hira, S. Bashiruddin, R. Warburton, J. Goto, B. Robert, D. J. Kwiatkowski, G. A. Finlay, Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin. Hum. Mol. Genet. 20, 1290-1305 (2011).
35. D. W. Webb, R. D. Thomas, J. P. Osborne, Cardiac rhabdomyomas and their association with tuberous sclerosis. Arch. Dis. Child. 68, 367-370 (1993).
36. K. B. S. Pasumarthi, H. Nakajima, H. O. Nakajima, S. Jing, L. J. Field, Enhanced cardiomyocyte DNA synthesis during myocardial hypertrophy in mice expressing a modified TSC2 transgene. Circ. Res. 86, 1069-1077 (2000).
37. J. Huang, B. D. Manning, The TSC1-TSC2 complex: A molecular switchboard controlling cell growth. Biochem. J. 412, 179-190 (2008).
38. E. Lesma, S. M. Sirchia, S. Ancona, S. Carelli, S. Bosari, F. Ghelma, E. Montanari, A. M. Di Giulio, A. Gorio, The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells. Am. J. Pathol. 174, 2150-2159 (2009).
39. P. K. Battiprolu, B. Hojayev, N. Jiang, Z. V. Wang, X. Luo, M. Iglewski, J. M. Shelton, R. D. Gerard, B. A. Rothermel, T. G. Gillette, S. Lavandero, J. A. Hill, Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J. Clin. Invest. 122, 1109-1118 (2012).
40. J. M. Berry, V. Le, D. Rotter, P. K. Battiprolu, B. Grinsfelder, P. Tannous, J. S. Burchfield, M. Czubryt, J. Backs, E. N. Olson, B. A. Rothermel, J. A. Hill, Reversibility of adverse, calcineurin-dependent cardiac remodeling. Circ. Res. 109, 407-417 (2011).
41. X. Lian, J. Zhang, K. Zhu, T. J. Kamp, S. P. Palecek, Insulin inhibits cardiac mesoderm, not mesendoderm, formation during cardiac differentiation of human pluripotent stem cells and modulation of canonical Wnt signaling can rescue this inhibition. Stem Cells 31, 447-457 (2013).